文章：

VEGF抑制剂改善多种癌症类型肝转移患者的生存结局——一项荟萃分析

VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types—A Meta-Analysis

原文发布日期：16 October 2023

DOI: 10.3390/cancers15205012

类型: Article

开放获取: 是

英文摘要：

Background: Liver metastases are associated with poor prognosis across cancers. Novel treatment strategies to treat patients with liver metastases are needed. This meta-analysis aimed to assess the efficacy of vascular endothelial growth factor inhibitors in patients with liver metastases across cancers. Methods: A systematic search of PubMed, Cochrane CENTRAL, and Embase was performed between January 2000 and April 2023. Randomized controlled trials of patients with liver metastases comparing standard of care (systemic therapy or best supportive care) with or without vascular endothelial growth factor inhibitors were included in the study. Outcomes reported included progression-free survival and overall survival. Results: A total of 4445 patients with liver metastases from 25 randomized controlled trials were included in this analysis. The addition of vascular endothelial growth factor inhibitors to standard systemic therapy or best supportive care was associated with superior progression-free survival (HR = 0.49; 95% CI, 0.40–0.61) and overall survival (HR = 0.83; 95% CI, 0.74–0.93) in patients with liver metastases. In a subgroup analysis of patients with versus patients without liver metastases, the benefit with vascular endothelial growth factor inhibitors was more pronounced in the group with liver metastases (HR = 0.44) versus without (HR = 0.57) for progression-free survival, but not for overall survival. Conclusion: The addition of vascular endothelial growth factor inhibitors to standard management improved survival outcomes in patients with liver metastasis across cancers.

摘要翻译： 

背景：肝转移与多种癌症的不良预后相关，亟需针对肝转移患者的新型治疗策略。本荟萃分析旨在评估血管内皮生长因子抑制剂对各类癌症肝转移患者的疗效。 方法：本研究系统检索了2000年1月至2023年4月期间PubMed、Cochrane CENTRAL和Embase数据库，纳入比较标准治疗（全身治疗或最佳支持治疗）联合或不联合血管内皮生长因子抑制剂的肝转移患者随机对照试验。报告结局包括无进展生存期和总生存期。 结果：本研究共纳入25项随机对照试验中的4445例肝转移患者。在标准全身治疗或最佳支持治疗基础上加用血管内皮生长因子抑制剂，与肝转移患者更优的无进展生存期（HR=0.49；95% CI 0.40-0.61）和总生存期（HR=0.83；95% CI 0.74-0.93）显著相关。亚组分析显示，在无进展生存期方面，血管内皮生长因子抑制剂对肝转移患者（HR=0.44）的获益较非肝转移患者（HR=0.57）更为显著，但总生存期未见此差异。 结论：在标准治疗方案中联合血管内皮生长因子抑制剂可改善各类癌症肝转移患者的生存结局。

原文链接：

VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types—A Meta-Analysis